Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2021-01-13
• Target enrollment: 0
• Participant gender: All

Summary

Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in subjects with resectable, early-stage (Stage I [>2cm] to IIIA) non-small cell lung cancer (NSCLC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedImmune LLC
• Treatments: Antibodies, Monoclonal; Durvalumab

Criteria

Inclusion Criteria:

1. Cytologically and/or histologically-documented NSCLC

1. Stage I (> 2 cm) to IIIA (for subjects with N2 disease, only those with 1 single nodal station ≤ 3 cm are eligible) NSCLC according to the 8th edition of American Joint Committee on Cancer staging classification

2. Amenable to complete surgical resection

3. Have not received any other therapy for this condition

2. Age ≥18 years old

3. Predicted FEV1 ≥ 50%

4. Predicted DLCO ≥ 50%

5. ECOG 0 or 1

6. Adequate organ function

Exclusion Criteria:

1. Subjects with small-cell lung cancer or mixed small-cell lung cancer

2. Subjects who require or may require pneumonectomy

3. Prior treatment with PD-L1, PD-L1, or CTLA-4 inhibitors

4. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug.

5. Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:

1. Subjects with vitiligo or alopecia

2. Subjects with hypothyroidism on hormone replacement

3. Any chronic skin condition that does not require systemic therapy

4. Subjects without active disease in the last 5 years may be included but only after consultation with the study physician

5. Subjects with celiac disease controlled by diet alone

6. Pregnant or breast-feeding female

7. Major surgical procedure within prior 30 days

8. History of active primary immunodeficiency

9. Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV

10. QTc interval (QTc) ≥ 470 ms

11. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent

12. Receipt of live attenuated vaccination within 30 days prior to study entry

13. History of another primary malignancy except for:

1. Curative-treated malignancy with no known active disease > 2 years before enrollment on the study

2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ